GBR 830Alternative Names: GBR830
Latest Information Update: 16 May 2016
Price : $50
At a glance
- Originator Glenmark Pharmaceuticals S.A.
- Class Monoclonal antibodies
- Mechanism of Action OX40 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Phase I Autoimmune disorders
- Preclinical Inflammatory bowel diseases; Rheumatoid arthritis